Drugs / Pegylated Interfon Alpha 2B
Pegylated Interfon Alpha 2B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00621439 | Mar 2007 → Jun 2008 | ocular melanoma | Emory University | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated Interfon Alpha 2B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00621439 ↗ |
| Known as | PEG-IFN | “The purpose of this study is to explore whether the drug pegylated-interferon-alfa-2b (PEG-IFN) has any effect on a certain type of immune cell” NCT00621439 ↗ |
| Known as | pegylated-interferon-alfa-2b | “The purpose of this study is to explore whether the drug pegylated-interferon-alfa-2b (PEG-IFN) has any effect on a certain type of immune cell” NCT00621439 ↗ |
| Route | Subcutaneous | “6 mcg/kg subcutaneously” NCT00621439 ↗ |